Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus rating of “Hold” from the six brokerages that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $70.75.

PBH has been the topic of a number of research analyst reports. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Finally, Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th.

Insider Activity

In related news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the transaction, the vice president owned 42,820 shares in the company, valued at $2,354,671.80. This represents a 2.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its stake in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after acquiring an additional 219 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in Prestige Consumer Healthcare during the 4th quarter worth $29,000. Geneos Wealth Management Inc. raised its position in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the last quarter. Torren Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter valued at $35,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock opened at $50.29 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.25 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $2.38 billion, a price-to-earnings ratio of 12.86, a P/E/G ratio of 1.61 and a beta of 0.35. Prestige Consumer Healthcare has a 1-year low of $42.62 and a 1-year high of $75.63. The firm’s 50-day moving average price is $48.30 and its two-hundred day moving average price is $56.47.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. During the same period in the previous year, the business posted $1.32 EPS. The business’s quarterly revenue was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, equities analysts predict that Prestige Consumer Healthcare will post 4.45 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).